Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015', provides an overview of the Chemotherapy Induced Neutropenia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chemotherapy Induced Neutropenia Overview 10 Therapeutics Development 11 Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11 Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12 Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13 Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 15 Chemotherapy Induced Neutropenia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Chemotherapy Induced Neutropenia - Products under Development by Companies 20 Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 22 Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 23 Apotex, Inc. 23 Biogenomics Limited 24 Bolder Biotechnology, Inc. 25 Cellerant Therapeutics, Inc. 26 Chong Kun Dang Pharmaceutical Corp. 27 Dr. Reddy's Laboratories Limited 28 Generon (Shanghai) Corporation Ltd. 29 Genexine, Inc. 30 Hanmi Pharmaceuticals, Co. Ltd. 31 Hospira, Inc. 32 Myelo Therapeutics GmbH 33 Octapharma AG 34 Pfenex Inc. 35 Pfizer Inc. 36 PharmaEssentia Corporation 37 Reliance Life Sciences Pvt. Ltd. 38 Richter Gedeon Nyrt. 39 Sandoz International GmbH 40 UAB Profarma 41 USV Limited 42 Welichem Biotech Inc. 43 Chemotherapy Induced Neutropenia - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 BBT-007 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BBT-015 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BBT-018 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 EC-18 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 eflapegrastim - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 F-627 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 filgrastim - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 filgrastim - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 filgrastim - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 filgrastim - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 filgrastim - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 filgrastim - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 GW-003 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 GXG-3 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Myelo-001 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 pegfilgrastim - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 pegfilgrastim - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 pegfilgrastim - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 pegfilgrastim - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 pegfilgrastim - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 pegfilgrastim - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 pegfilgrastim - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 pegfilgrastim - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 pegfilgrastim - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 pegfilgrastim - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 pegfilgrastim - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 pegfilgrastim - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Recombinant Protein for Chemotherapy Induced Neutropenia - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 romyelocel-L - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 TXA-302 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 WBI-2100 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Chemotherapy Induced Neutropenia - Recent Pipeline Updates 86 Chemotherapy Induced Neutropenia - Dormant Projects 91 Chemotherapy Induced Neutropenia - Discontinued Products 93 Chemotherapy Induced Neutropenia - Product Development Milestones 94 Featured News & Press Releases 94 Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 94 Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 95 May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 95 Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 96 Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 97 May 10, 2011: Dr Reddy's Launches Pegfilgrastim In India Under Brand Name Peg-grafeel 97 Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 97 Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology 98 Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia 98 Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants 98 Appendix 100 Methodology 100 Coverage 100 Secondary Research 100 Primary Research 100 Expert Panel Validation 100 Contact Us 100 Disclaimer 101
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2015 11 Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 14 Number of Products under Investigation by Universities/Institutes, H2 2015 15 Comparative Analysis by Late Stage Development, H2 2015 16 Comparative Analysis by Clinical Stage Development, H2 2015 17 Comparative Analysis by Early Stage Development, H2 2015 18 Comparative Analysis by Unknown Stage Development, H2 2015 19 Products under Development by Companies, H2 2015 20 Products under Development by Companies, H2 2015 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2015 22 Chemotherapy Induced Neutropenia - Pipeline by Apotex, Inc., H2 2015 23 Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H2 2015 24 Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H2 2015 25 Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2015 26 Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 27 Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 28 Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015 29 Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H2 2015 30 Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 31 Chemotherapy Induced Neutropenia - Pipeline by Hospira, Inc., H2 2015 32 Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2015 33 Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2015 34 Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H2 2015 35 Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H2 2015 36 Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H2 2015 37 Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2015 38 Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2015 39 Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2015 40 Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H2 2015 41 Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H2 2015 42 Chemotherapy Induced Neutropenia - Pipeline by Welichem Biotech Inc., H2 2015 43 Assessment by Monotherapy Products, H2 2015 44 Number of Products by Stage and Target, H2 2015 46 Number of Products by Stage and Mechanism of Action, H2 2015 48 Number of Products by Stage and Route of Administration, H2 2015 50 Number of Products by Stage and Molecule Type, H2 2015 52 Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H2 2015 86 Chemotherapy Induced Neutropenia - Dormant Projects, H2 2015 91 Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H2 2015 92 Chemotherapy Induced Neutropenia - Discontinued Products, H2 2015 93
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.